ABL1 and leukemia: To test our RoCK and ROI targeted enrichment strategy, we used a mix of three patient-derived leukemia cell lines containing either a minor fusion (SUP-B15, e1a2), major fusion (K562, e14a2) or no BCR::ABL1 fusion (Loucy) (Fig. 7b, Supplementary Table 1 and Supplementary Data 1).